Serum oxalate rises in uremia because of decreased renal clearance, and crystals of calcium oxalate occur in the tissues of uremic patients. Crystal formation suggests that either uremic serum is supersaturated with calcium oxalate, or local oxalate production or accumulation causes regional supersaturation. To test the first alternative, we ultrafiltered uremic serum and measured supersaturation with two different methods previously used to study supersaturation in urine. First, the relative saturation ratio (RSR), the ratio of the dissolved calcium oxalate complex to the thermodynamic calcium oxalate solubility product, was estimated for 11 uremic (before and after dialysis) and 4 normal serum samples using a computer program. Mean ultrafiltrate oxalate predialysis was 89 +/-8 microM/liter (+/-SEM), 31 +/-4 postdialysis, and 10 +/-3 in normals. Mean RSR was 1.7 +/-0.1 (predialysis), 0.7 +/-0.1 (postdialysis), and 0.2 +/-0.1 (normal), where values greater than 1 denote supersaturation, less than 1, undersaturation. Second, the concentration product ratio (CPR), the ratio of the measured calcium oxalate concentration product before to that after incubation of the sample with calcium oxalate monohydrate crystal, was measured in seven uremic and seven normal serum ultrafiltrates. Mean oxalate was 91 +/-11 (uremic) and 8 +/-3 (normal). Mean CPR was 1.4 +/-0.2 (uremic) and 0.2 +/-0.1 (normal different methods previously used to study supersaturation in urine. First, the relative saturation ratio (RSR), the ratio of the dissolved calcium oxalate complex to the thermodynamic calcium oxalate solubility product, was estimated for 11 uremic (before and after dialysis) and 4 normal serum samples using a computer program. Mean ultrafiltrate oxalate predialysis was 89±8 ,uM/liter (±SEM), 31±4 postdialysis, and 10±3 in normals. Mean RSR was 1.7±0.1 (predialysis), 0.7±0.1 (postdialysis), and 0.2±0.1 (normal), where values >1 denote supersaturation, <1, undersaturation. Second, the concentration product ratio (CPR), the ratio of the measured calcium oxalate concentration product before to that after incubation of the sample with calcium oxalate monohydrate crystal, was measured in seven uremic and seven normal serum ultrafiltrates. Mean oxalate was 91±11 (uremic) and 8±3 (normal). Mean CPR was 1.4±0.2 (uremic) and 0.2±0.1 (normal). Predialysis, 17 of 18 uremic ultrafiltrates were supersaturated with respect to calcium oxalate. The degree of supersaturation was correlated with ultrafiltrate oxalate (RSR, r = 0.99, n = 29, P < 0.001; CPR, r = 0.75, n = 11, P < 0.001). A value of ultrafiltrate oxalate of 50 AM/liter separated undersaturated from supersaturated samples and occurred at a creatinine of -9.0 mg/dl.
Introduction
Serum oxalate concentration increases during chronic renal failure (1, 2) , and is above normal in virtually all patients who require chronic dialysis (3) (4) (5) , because oxalate is removed from the body almost entirely by filtration at the renal glomerulus (6) (7) (8) and by secretion in the early portions of the proximal tubules (9-1 1). In some patients with chronic renal failure, crystals of calcium oxalate have been identified in kidney, blood vessels, myocardium, thyroid, synovia, cartilage, bone, and periodontium (12) (13) (14) (15) (16) (17) . The formation of crystals indicates that calcium oxalate concentrations in these tissues must have exceeded the solubility limit on some occasions, but the mechanism by which this occurs is not clear. Tissue calcium and oxalate concentrations could exceed the solubility limit because the serum itself is supersaturated with respect to calcium oxalate. Alternatively, the tissues may selectively accumulate calcium or oxalate, or they may produce oxalate. Heart, kidney, liver, erythrocytes, and leukocytes are all known to produce oxalate ( 18, 19) , and, at least in kidney, tissue oxalate levels can exceed those of blood (20) .
Hyperoxalemia could, but need not necessarily, cause serum supersaturation. Serum oxalate levels reported in patients with chronic renal failure have ranged from 22 to 200 ,uM/liter (1-5, 14, 21-23) , and blood ionized calcium is generally -1 mM (24) . The chemical product of calcium ion and total oxalate is therefore -22-200 X 10-9 M2, far above the ion activity product of 2.25 X 10-9 M2, which has been determined for simple so- lutions at thermodynamic equilibrium with a solid phase of calcium oxalate monohydrate (25). However, the fraction ofserum oxalate that is free, not involved in soluble complexes with sodium, potassium, calcium, and other cations, is unknown: in urine <50% is usually free (25, 26) . The divalent activity coefficient in solutions containing 140 mM sodium is -0.325 (25), so the free-ion activity product may be estimated as (0.325) X (0.5) X (measured oxalate) X (0.325) X (1 mM) or -1.16-10.6 X l0-9 M2. In other words, calculated estimates range from below to above the solubility limit, so the likelihood of serum supersaturation in chronic renal failure is difficult to gauge, and measurements of supersaturation are essential.
We have measured serum supersaturation with respect to calcium oxalate monohydrate using two independent methods, both of which have been used to estimate supersaturation in urine (25, 27, 28) . One method (25) uses an iterative computer model of the polyelectrolyte equilibria of serum ultrafiltrates to calculate the calcium oxalate free-ion activity product, from which the solution activity of dissolved calcium oxalate complex [CaOx] is calculated. This value, divided by the known solubility of [CaOx] in aqueous solution (6.16 X 10-6 M) (25), is the relative supersaturation ofthe serum with respect to calcium oxalate. In the other method (27, 28) , serum ultrafiltrates are incubated with preformed crystals of calcium oxalate monohydrate for a period long enough to permit the attainment ofthermodynamic equilibrium; the ratio of the calcium oxalate chemical product before to that at the end of the incubation, the concentration product ratio (CPR),' gives a direct estimate of supersaturation.
In addition, we have estimated serum supersaturation with respect to four other materials that could produce soft tissue crystal deposits: hydroxyapatite, brushite, calcium carbonate, and sodium hydrogen urate (29, 30) .
Methods
Patients and normal subjects Activity products and relative supersaturation with respect to calcium oxalate, hydroxyapatite, brushite, calcium carbonate, and sodium hydrogen urate were calculated by using measurements made in fasting serum and serum ultrafiltrates from 11 patients with chronic renal failure receiving thrice-weekly hemodialysis for at least 1 yr, 3 patients with chronic renal insufficiency who did not require dialysis, and 4 normal subjects. No patient had primary hyperoxaluria or renal stones. In dialysis patients, blood samples were drawn from their arteriovenous fistulas immediately predialysis-prior to the administration of heparin-and at the end of 4 h of dialysis. Patients took their usual medications, including multivitamins containing pyridoxine and 100-200 mg of vitamin C. In the three patients with chronic renal insufficiency and the four normal subjects, samples for pH, carbon dioxide tension (Pco2), and ionized calcium were obtained from arterialized venous blood (31) , and antecubital venous blood was used for all other measurements. Each patient and normal subject collected a 24-h urine sample during the day prior to blood drawing. Oxalate excretion was 23±2 mg/24 h (mean±SEM) in the four normal subjects, 30±3 in the three patients with renal insufficiency (P = NS vs. normal subjects), and 4±1 in the six dialysis patients who produced urine (P < 0.001 vs. both groups).
Using the same blood sampling methods, direct supersaturation measurements were made on serum ultrafiltrates from an additional seven patients receiving hemodialysis, and seven normal subjects; postdialysis measurements were precluded by the heparin given during dialysis, which slows the growth ofthe seed crystals (32). It was not possible to measure supersaturation and also calculate free ion products in the same blood samples, because this would have necessitated drawing excessive amounts of blood from each patient (-150 ml).
Supersaturation measurements
Calculated values. The calcium oxalate ion activity product was calculated using a computer program (25), with the measurements shown in Table  I . The computer program calculates free ion concentrations using the concentrations of ligands and known stability constants for each of 62 species. Inasmuch as we actually measured ionized calcium, we were able to insert this known value in the program for each patient. Divalent ion activity coefficients were calculated from ionic strength in a conventional manner, using the Davies modification of the Debye-Huckel solution to the Poisson-Boltzmann equation (25 (Table II) . Ratios of 1 connote a sample at equilibrium, above 1, supersaturation, and below I undersaturation (25, 33).
Directly measured supersaturation. Ionized calcium was measured in whole blood, and total calcium and oxalate were measured in serum ultrafiltrates, which were then adjusted to pH 7.40, and seeded with 10 mg/ml of preformed calcium oxalate monohydrate (CaOx) crystals (27, 28, 34) . After 48 h of incubation at 370C with constant stirring, the crystals were removed by filtration through a 0.22-MUm Millipore filter (Millipore Corp., Bedford, MA), and total and ionized calcium and total oxalate were remeasured. The ratio ofthe calcium oxalate concentration product before to that after incubation, the CPR, was calculated using both the ionized and ultrafilterable calcium. Results from both calculations were similar ( Oxalate can be produced after blood has been drawn, in vitro. Oxalate may be produced nonenzymatically in serum (36) ; rapid ultrafiltration and precipitation, used here, minimize this source oferror. Erythrocytes and leukocytes can produce oxalate through enzymatic oxidation of glyoxylate (19, 37 ), but we did not wish to add conventionally used enzyme inhibitors (37) to blood samples because of their possible interactions with oxalate, calcium, or other blood ligands. We found no increase in oxalate in a pooled serum sample from five normal volunteers, collected without inhibitors, over 30 min on ice; the 30-min and starting values were both 3.6 MM/liter. For patients with renal insufficiency or uremia, the issue of in vitro production in serum is less important than in normals, because the in vitro increments observed by others over periods ofgreater duration (36) Oxalate. Oxalic acid was determined as the dihydroxy-quinoxaline derivative (38) using high-performance liquid chromatography (HPLC) with a C-18 reversed-phase column. After ultrafiltration, oxalate was precipitated from ultrafiltrates or buffers with saturated calcium sulfate in ethanol. The precipitate was dried and dissolved in 0.5 N ortho-phenylenediamine in 4 N HCI; concentrated HCI was added, and tubes were heated to 1 10°C for 20 min. The resulting derivative was extracted with ethyl acetate and 8 M NaOH, and the extracted compounds were dried under nitrogen. They were redissolved in distilled water and prefiltered through a 0.5-jum Millex-SR filter (Millipore Corp.), before being separated and quantitated on an Altex Ultrasphere ODS reversed-phase HPLC column (Altex Scientific Inc., Berkeley, CA) (0.46 x 25 cm), using a linear methanol gradient (5-30%) in 0.35 M ammonium acetate, monitored at 31 1 nm. The dihydroxy-quinoxaline derivative eluted as a single peak at 17±1 min ( Fig. 1 ). Because dicarboxylic acids and a-keto acids form similar derivatives with ortho-phenylenediamine (39), derivatives of a-ketoglutaric acid, fumaric acid, glyoxylic acid, phenylpyruvic acid, pyruvic acid, and succinic acid were made. None of these derivatives eluted at a retention time of 17±1 min under the conditions used in this analysis.
Using aqueous standards of derivatized oxalic acid, the area under the 17-min elution peak increased linearly with oxalate concentration over the range of 2.5-40 MM (Fig. 2) . The area of the oxalic acid peak was calculated using an integrator (model 3390 A, Hewlett-Packard Co., Palo Alto, CA) connected to a spectrophotometer (model 100-10, Hitachi, Tokyo, Japan). Recovery of [14C]oxalate added to normal ultrafiltrates was 32±1% in 19 experiments; in eight uremic ultrafiltrates, recovery was 29±3% (P = NS, vs. normal). Recovery of ['4CJoxalate added to standards was 25±1%. Inasmuch as recoveries were very consistent, they were not measured in the uremic patients. However, in the normals, the recoveries for the CPR measurements were individually calculated because levels of oxalate are low, raising the likelihood of error; in this group, recovery was 36±1%. In 12 uremic serum ultrafiltrates, oxalate was measured using both the HPLC and the zinc reduction methods (40) Oxalate Concentration (ILMIU) Figure 2 . Calibration curve for HPLC method using aqueous oxalate standards. Standards were derivatized in the same manner as serum samples (Fig. 1 groups). Although the mean ion product was below the solubility limit in the chronic renal failure patients after dialysis, and in the three patients with chronic renal insufficiency, both still exceeded that ofnormal subjects (P < 0.01, for both). The calcium oxalate relative supersaturation for the individual samples in all four groups (Fig. 4) Figure 3 . Calculated calcium oxalate ion activity products in serum samples from 4 normals, 3 patients with chronic renal insufficiency, and 11 uremic patients before and after dialysis (see Methods). Values are mean±SEM. The known thermodynamic solubility product (4) of calcium oxalate at equilibrium (2.25 X 10-M2, see Finlayson [25] ) is shown as a horizontal line. *Differs from all other groups, P < 0.01, and less than 4, P < 0.01. +Differs from all other groups, P < 0.01, and greater than 4, P < 0.01. Ionized calcium was measured in blood, total calcium and oxalate in ultrafiltrates, and CPR was calculated using both ionized and total calcium values with similar results. Despite the great n in Table II . Values of CPR calculated with ultrafilterable differences ofapproach, CPR and calculated supersaturation are im (Fig. 4) (Fig. 4) ; CPR is generally lower icant differences in the final regressions (F = 12.0; than RSR. This difference is reminiscent of, though not exactly 1.001).
comparable to, differences of these two methods applied to urine mple buffered salt solutions with no initial calcium or ox- (34) (27, 28, 33) . Both the calculation and CPR approaches were, in fact, originally designed to estimate calcium oxalate supersaturation in urine (27, 33) , and have been widely used for this purpose (28, 34) . It is not surprising that calcium oxalate supersaturation in blood is similar to that ofurine, as the blood oxalate level rises to urine levels as the kidneys fail. A major potential difference between blood and urine is that urine contains powerful inhibitors of calcium oxalate crystal growth (49, 50) and nucleation (27, 5 1) , whereas blood may or may not. The degree of supersaturation needed to initiate crystal formation, called the formation product, is higher in urine than in simple salt solutions (27) , presumably because of inhibitors. The formation product is not known for plasma, ultrafiltrates, or blood. An inhibitor, if present in blood, could increase the formation product and alter the degree of crystallization produced by a given supersaturation.
The relationship between the level of renal function and the degree ofsupersaturation, although very important, is not known in detail. Our studies of three patients suggest that at creatinine levels as high as [6] [7] [8] 37, 57) , and from this study, allows us to construct a reasonable regression relationship, which suggests a creatinine of 9 mg/dl as the level at which supersaturation would almost universally occur in chronic renal failure (Fig. 5) , and a level of about 7 mg/dl at which supersaturation would first occur.
Blood calcium oxalate supersaturation probably is responsible for the crystals of calcium oxalate seen in kidney, myocardium, blood vessels, and other tissues (12) (13) (14) (15) (16) (17) in patients with uremia. These deposits have been associated with conduction defects (16), congestive heart failure (16, 58) , arthritis (14) , bone disease (55), periodontal disease (17) , granulomas (59) , and a vasculitis-like syndrome (15) . Calcium (57); (e) the present study. Three points are superimposed where creatinine = 1 mg/dl and oxalate = 5 IAM/liter. Oxalate = 5.2 X creatinine + 2.34 (r = 0.84, n = 57, P < 0.001). Serum oxalate seems to achieve a value of 40-50 utM/liter, the lower limits of supersaturation, at serum creatinine values of -9 mg/dl.
We have shown that dialysis lowers supersaturation, so one might expect well-dialyzed patients to have fewer deposits than patients whose dialysis has been delayed or inadequate. Salyer and Keren (13) found fewer deposits in patients treated by chronic hemodialysis than in those receiving peritoneal dialysis or in undialyzed patients with chronic renal failure.
Other maneuvers that lower supersaturation may also reduce deposits. Pyridoxine may lower serum oxalate levels in renal failure patients; Balcke and co-workers (65) 
